Case Report: Venetoclax plus ICE as a bridge to allogeneic hematopoietic stem cell transplantation in chemorefractory hepatosplenic T-cell lymphoma
Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare and highly aggressive mature T-cell neoplasm characterized by preferential involvement of the spleen, liver, and bone marrow. Conventional chemotherapy frequently results in primary refractory disease or short-lived responses, and effective salvage strategies remain limited. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a potentially curative approach in eligible patients who achieve adequate disease control. Case presentation A 21-year-old man presented with severe cytopenias, massive splenomegaly, and bone marrow involvement. Expert pathological review demonstrated predominantly sinusoidal infiltration by cytotoxic T cells expressing CD2, CD3, CD5, CD7, CD8, granzyme B, and TIA-1, supporting the diagnosis of HSTCL. The patient showed no meaningful response to CHOEP and subsequently developed progressive disease following Hyper-CVAD. Venetoclax was therefore incorporated into an ICE chemotherapy backbone. Venetoclax was administered at 800 mg once daily for 10 days. Following the first cycle of venetoclax plus ICE (Ven-ICE), splenic craniocaudal length decreased from approximately 25 cm to 14 cm. After two cycles, the reduction in disease burden was maintained, and the patient proceeded to allo-HSCT from a fully HLA-matched related donor. At approximately 30 days after allo-HSCT, blood counts had substantially recovered, with a white blood cell count of 4.65 × 10 9 /L, absolute neutrophil count of 3.15 × 10 9 /L, hemoglobin of 11.4 g/dL, platelet count of 135 × 10 9 /L, and LDH of 284 U/L. Bone marrow examination showed no morphologic evidence of recurrent HSTCL, and flow cytometry detected no clonal T-cell population. At the most recent follow-up, approximately 3.5 months after allo-HSCT, the patient remained in remission, with no clinical evidence of acute GVHD. Conclusion Ven-ICE provided rapid disease reduction after failure of CHOEP and Hyper-CVAD and created a therapeutic window for subsequent allo-HSCT in this patient with chemorefractory HSTCL. Because ICE has established activity in HSTCL and BCL-2 dependence was not assessed, the independent contribution of venetoclax cannot be determined. This case supports further investigation of venetoclax-containing combination strategies as a potential bridge to transplantation in refractory HSTCL.
Authors
- Turgay Ulaş (ORCID: https://orcid.org/0000-0001-9332-663X)
- Sinem Kul
- Burcu Aslan Candır (ORCID: https://orcid.org/0000-0003-3386-8984)
- Mehmet Sinan Dal (ORCID: https://orcid.org/0000-0002-5994-2735)
- Vehbi Demircan (ORCID: https://orcid.org/0000-0002-0378-8687)
- Fevzi Altuntaş (ORCID: https://orcid.org/0000-0002-7160-7630)
- Tuğba Zorlu (ORCID: https://orcid.org/0000-0001-5108-381X)
- Hakan Eminoglu (ORCID: https://orcid.org/0009-0007-2509-8808)
- Busra Altinoz
- Emre Can Kaleycik
Institutions
- Dicle University (TR)
- Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR)
- Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital (TR)
Publication Details
- Journal
- Frontiers in Hematology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/frhem.2026.1992219
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00